168 related articles for article (PubMed ID: 15661026)
1. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
Pesu M; Candotti F; Husa M; Hofmann SR; Notarangelo LD; O'Shea JJ
Immunol Rev; 2005 Feb; 203():127-42. PubMed ID: 15661026
[TBL] [Abstract][Full Text] [Related]
2. Jak3 and the pathogenesis of severe combined immunodeficiency.
O'Shea JJ; Husa M; Li D; Hofmann SR; Watford W; Roberts JL; Buckley RH; Changelian P; Candotti F
Mol Immunol; 2004 Jul; 41(6-7):727-37. PubMed ID: 15220007
[TBL] [Abstract][Full Text] [Related]
3. JAK3 inhibition as a new concept for immune suppression.
Borie DC; Si MS; Morris RE; Reitz BA; Changelian PS
Curr Opin Investig Drugs; 2003 Nov; 4(11):1297-303. PubMed ID: 14758768
[TBL] [Abstract][Full Text] [Related]
4. Dysfunctional cytokine receptor signaling in severe combined immunodeficiency.
Leonard WJ
J Investig Med; 1996 Aug; 44(6):304-11. PubMed ID: 8795294
[TBL] [Abstract][Full Text] [Related]
5. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.
Notarangelo LD; Mella P; Jones A; de Saint Basile G; Savoldi G; Cranston T; Vihinen M; Schumacher RF
Hum Mutat; 2001 Oct; 18(4):255-63. PubMed ID: 11668610
[TBL] [Abstract][Full Text] [Related]
6. Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene.
Villa A; Sironi M; Macchi P; Matteucci C; Notarangelo LD; Vezzoni P; Mantovani A
Blood; 1996 Aug; 88(3):817-23. PubMed ID: 8704236
[TBL] [Abstract][Full Text] [Related]
7. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain.
Mella P; Schumacher RF; Cranston T; de Saint Basile G; Savoldi G; Notarangelo LD
Hum Mutat; 2001 Oct; 18(4):355-6. PubMed ID: 11668621
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency.
Vihinen M; Villa A; Mella P; Schumacher RF; Savoldi G; O'Shea JJ; Candotti F; Notarangelo LD
Clin Immunol; 2000 Aug; 96(2):108-18. PubMed ID: 10900158
[TBL] [Abstract][Full Text] [Related]
9. Unexpected and variable phenotypes in a family with JAK3 deficiency.
Frucht DM; Gadina M; Jagadeesh GJ; Aksentijevich I; Takada K; Bleesing JJ; Nelson J; Muul LM; Perham G; Morgan G; Gerritsen EJ; Schumacher RF; Mella P; Veys PA; Fleisher TA; Kaminski ER; Notarangelo LD; O'Shea JJ; Candotti F
Genes Immun; 2001 Dec; 2(8):422-32. PubMed ID: 11781709
[TBL] [Abstract][Full Text] [Related]
10. A new modality for immunosuppression: targeting the JAK/STAT pathway.
O'Shea JJ; Pesu M; Borie DC; Changelian PS
Nat Rev Drug Discov; 2004 Jul; 3(7):555-64. PubMed ID: 15232577
[No Abstract] [Full Text] [Related]
11. Severe combined immunodeficiencies of the common gamma-chain/JAK3 signaling pathway.
Schumacher RF; Notarangelo LD
Isr Med Assoc J; 2002 Feb; 4(2):131-5. PubMed ID: 11875988
[No Abstract] [Full Text] [Related]
12. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
Borie DC; O'Shea JJ; Changelian PS
Trends Mol Med; 2004 Nov; 10(11):532-41. PubMed ID: 15519279
[TBL] [Abstract][Full Text] [Related]
13. Rapid protein-based assays for the diagnosis of T-B+ severe combined immunodeficiency.
Gilmour KC; Cranston T; Loughlin S; Gwyther J; Lester T; Espanol T; Hernandez M; Savoldi G; Davies EG; Abinun M; Kinnon C; Jones A; Gaspar HB
Br J Haematol; 2001 Mar; 112(3):671-6. PubMed ID: 11260071
[TBL] [Abstract][Full Text] [Related]
14. Is JAK3 a new drug target for immunomodulation-based therapies?
Papageorgiou AC; Wikman LE
Trends Pharmacol Sci; 2004 Nov; 25(11):558-62. PubMed ID: 15491777
[TBL] [Abstract][Full Text] [Related]
15. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.
Russell SM; Tayebi N; Nakajima H; Riedy MC; Roberts JL; Aman MJ; Migone TS; Noguchi M; Markert ML; Buckley RH; O'Shea JJ; Leonard WJ
Science; 1995 Nov; 270(5237):797-800. PubMed ID: 7481768
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation.
Säemann MD; Zeyda M; Stulnig TM; Böhmig GA; Wekerle T; Hörl WH; Zlabinger GJ
Transpl Int; 2004 Oct; 17(9):481-9. PubMed ID: 15368094
[TBL] [Abstract][Full Text] [Related]
17. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.
Cacalano NA; Migone TS; Bazan F; Hanson EP; Chen M; Candotti F; O'Shea JJ; Johnston JA
EMBO J; 1999 Mar; 18(6):1549-58. PubMed ID: 10075926
[TBL] [Abstract][Full Text] [Related]
18. Impaired IL-7 signaling may explain a case of atypical JAK3-SCID.
Li J; Nara H; Rahman M; Juliana FM; Araki A; Asao H
Cytokine; 2010 Feb; 49(2):221-8. PubMed ID: 19889552
[TBL] [Abstract][Full Text] [Related]
19. Combined immunodeficiencies due to defects in signal transduction: defects of the gammac-JAK3 signaling pathway as a model.
Notarangelo LD; Giliani S; Mella P; Schumacher RF; Mazza C; Savoldi G; Rodriguez-Pérez C; Badolato R; Mazzolari E; Porta F; Candotti F; Ugazio AG
Immunobiology; 2000 Aug; 202(2):106-19. PubMed ID: 10993286
[TBL] [Abstract][Full Text] [Related]
20. The role of Jak3 in lymphoid development, activation, and signaling.
Thomis DC; Berg LJ
Curr Opin Immunol; 1997 Aug; 9(4):541-7. PubMed ID: 9287175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
